Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML

Clinical trial NCT06679582 · TERMINATED

Trial details

NCT number: NCT06679582
Sponsor: Sutro Biopharma, Inc.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)

Start date: 2024-12-04
Primary completion: 2025-06-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.